Business Wire

TECHSTARS

14.9.2021 10:02:34 CEST | Business Wire | Press release

Share
Techstars Doubles Down on European Commitment With the Launch of Two New Accelerator Programs in Paris and Stockholm

Techstars , the worldwide network that helps entrepreneurs succeed, announces the launch of two new accelerator programs in Paris and Stockholm. The launch showcases Techstars’ commitment to investing in startup talent in Europe, where it plans to invest in more than 100 startups in 2022 through its various accelerator programs in seven countries. Both programs will be fully funded by Techstars, following the recent July close of a new $150 million fund , intended to support more local entrepreneurs looking for global exposure.

This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20210914005314/en/

The Paris Techstars Accelerator and Stockholm Techstars Accelerator will each accept 12 startups per class, who will benefit from up to $120k in funding alongside evergreen access to Techstars’ vast network of mentors, investors, alumni and corporate partners. The Paris accelerator will operate two classes per year, while Stockholm will run once in 2022 and twice per year from 2023 onwards. Applications for these accelerators open today and will close on 1 December 2021, with the first classes of both programs due to commence on 21 March 2022.

Applications will be accepted from startups across all high-growth sectors, both B2B and B2C, and successful applicants will have a strong founding team who are using technology to tackle complex problems, with a clear and scalable product-market fit.

The Paris and Stockholm Techstars Accelerator programs follow the recent appointment of French-born CEO, Maëlle Gavet, in January 2021. An experienced French entrepreneur and former executive at Compass and Booking.com, Gavet’s experience scaling companies across Europe will assist Techstars on its mission to help more entrepreneurs in more places transform the world through access to capital and a global network.

Techstars currently operates 47 accelerators in 33 cities and 12 countries around the world, and while it previously operated a Paris-based accelerator in partnership with corporate partners, the Stockholm Techstars Accelerator marks its first venture into Sweden as it eyes expansion opportunities across Europe. Since 2009 and 2010, the company has been actively supporting thousands of entrepreneurs in Paris and Stockholm, respectively, by hosting more than 90 Techstars Startup Weekend programs in both cities, in close collaboration with local ecosystem leaders. Additionally in Europe, Techstars operates programs in London, Amsterdam, Berlin, Oslo and Turin.

Since its inception in 2006, Techstars has invested in 2,589 companies, which today have a combined market capital valuation of $220.1 billion. It counts 15 unicorns among its accelerator graduates, including DigitalOcean, Chainalysis, PillPack and SendGrid. Techstars invests in approximately 500 startups and deploys approximately $130M per year, making it one of the largest investors in high-growth early-stage companies by volume in the world.

Maëlle Gavet, CEO of Techstars , said: “We believe in the power of local ecosystems and that life-changing ideas can come from anywhere in the world - you don’t need to be in Silicon Valley to be a success. At Techstars, we meet the founders where they are and use our local networks to give them access to world-class capital and investing opportunities they wouldn’t otherwise have. Paris and Stockholm are two of Europe’s most rapidly growing yet underserved tech hubs, and we know there is a huge amount of talent there ready to be harnessed.”

Applications to apply to the Paris Techstars Accelerator and Stockholm Techstars Accelerator are open now.

About Techstars

The Techstars worldwide network helps entrepreneurs succeed. Founded in 2006, Techstars began with three simple ideas—entrepreneurs create a better future for everyone, collaboration drives innovation, and great ideas can come from anywhere. Now we are on a mission to enable every person on the planet to contribute to, and benefit from, the success of entrepreneurs. In addition to operating accelerator programs and venture capital funds, we do this by connecting startups, investors, corporations, and cities to help build thriving startup communities. Techstars has invested in more than 2,589 companies with a combined market cap of more than $220.1B. www.techstars.com

Link:

ClickThru

Social Media:

https://facebook.com/techstars

About Business Wire

Business Wire
Business Wire
101 California Street, 20th Floor
CA 94111 San Francisco

http://businesswire.com

Subscribe to releases from Business Wire

Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.

Latest releases from Business Wire

Incyte Announces New Positive 54-Week Late-Breaking Data for Povorcitinib in Hidradenitis Suppurativa at the 2026 American Academy of Dermatology (AAD) Annual Meeting28.3.2026 20:00:00 CET | Press release

Phase 3 data from the STOP-HS program demonstrate povorcitinib’s substantial and durable clinical efficacy through Week 54 in patients with moderate to severe hidradenitis suppurativa (HS). Through Week 54, clinically meaningful and durable responses were observed across all groups in both STOP-HS1 and STOP-HS2, with up to 71.4% of patients achieving HiSCR50. Improvements in clinical responses across high stringent thresholds were observed, with up to 57% of participants achieving HiSCR75 and up to 29% of participants achieving HiSCR100. Povorcitinib treatment led to consistent reductions across key inflammatory lesion types, with full resolution (ANdT=0) achieved in up to 20% of patients. Additionally, clinically meaningful improvements in quality-of-life measures, including skin pain and fatigue, were observed at Week 54. The overall safety profile of povorcitinib through 54 weeks is consistent with previously reported data, and both doses were well tolerated. Incyte (Nasdaq:INCY) to

Takeda’s Zasocitinib Delivered Rapid and Durable Skin Clearance in a Convenient Once-Daily Pill, Affirming Promise to Reshape Psoriasis Care28.3.2026 20:00:00 CET | Press release

About 70% of patients treated with zasocitinib achieved clear or almost clear skin (sPGA 0/1) at week 16 in Phase 3 plaque psoriasis studies A significantly greater PASI 75 response rate versus placebo was observed as early as week 4 Safety profile consistent with Phase 2b studies with no new safety signals identified Takeda(TSE:4502/NYSE:TAK)today announced new data from the two pivotal Phase 3studies of zasocitinib (TAK-279), a next-generation, highly selective oral tyrosine kinase 2 (TYK2) inhibitor, in adults with moderate-to-severe plaque psoriasis (PsO).1 Presented as a late-breaking abstract at the 2026 American Academy of Dermatology (AAD) Annual Meeting, these data show that convenient once-daily oral zasocitinib demonstrated rapid and durable skin clearance with a safety profile consistent with Phase 2b studies.1,2 “Our goal in psoriasis treatment is clear or almost clear skin, and previously this has been achieved primarily with injectable therapies,” said Melinda Gooderham,

AAD 2026: Late-Breaking Nemolizumab Data Demonstrate Clinically Meaningful Benefits for Children Aged 2 to 11 With Moderate-to-Severe Atopic Dermatitis28.3.2026 16:00:00 CET | Press release

Pharmacokinetics, safety and efficacy clinical study data show that nemolizumab achieved clinically meaningful reductions in skin lesions and itch through Week 16, which were sustained up to a year in children aged 2 to 11 with moderate-to-severe atopic dermatitis1 These findings reinforce the previously established safety and efficacy of nemolizumab in adults and adolescents with moderate-to-severe atopic dermatitis, for which it is approved by multiple global regulatory authorities2,3 Up to 25% of children are affected by atopic dermatitis, and currently there are limited approved treatment options for children living with moderate-to-severe atopic dermatitis4,5 Galderma (SIX: GALD) today announced new phase II data showing that nemolizumab was well tolerated and effective in children (aged 2 to 11 years) with moderate-to-severe atopic dermatitis, with a clinically meaningful and sustained reduction in skin lesions and itch for up to a year.1 Results will be presented in a late-break

Angelalign Technology (6699.HK)Releases 2025 Results: Passion for Clinical Excellence Drives Worldwide Growth27.3.2026 20:56:00 CET | Press release

Angelalign Technology Inc. (6699.HK) (“Angel” or the “Company”) released its financial results for fiscal year 2025. During the reporting period, the Company continued to do well in both the global and China markets. Total case volume was 532,400, which increased 48.1%, revenue was USD 370.3 million, which increased 37.8%, and adjusted net profit was USD 43.8 million, which increased 63.0%. The results were driven by Angel’s passion for clinical excellence and its open and inclusive culture that empowers talented people to work together to meet customer needs, the Company said. Fox Hu, CEO of Angel, stated: “The clear aligner industry is complex and multidisciplinary. It requires top-tier technical and operational talent along with seamless collaboration among professionals from diverse geographies. Angel’s open and inclusive culture attracts professionals who share a passion for clinical excellence and a dedication to bringing outstanding products and services to customers. This melti

Axway Positioned as a Leader in the IDC MarketScape: Worldwide API Management 2026 Vendor Assessment27.3.2026 18:46:00 CET | Press release

Axway, a 74Software company (Euronext: 74SW) and global leader in federated API management and enterprise integration, has been named a Leader in the IDC MarketScape: Worldwide API Management 2026 Vendor Assessment.1 Axway Amplify securely connects, orchestrates, and automates data integration. Organizations in financial services, manufacturing, healthcare, and other industries rely on Amplify to modernize integrations and confidently unlock data to deliver superior digital services faster. The report notes: “The platform benefits from Axway’s long-standing experience in B2B integration, secure file transfer, and legacy connectivity, providing differentiated capabilities for organizations that need to expose and control APIs around core systems that are not cloud-native.”1 This multi-pattern expertise in security, integration, and federated governance — built during the early phases of the API-driven digital transformation — becomes especially critical as enterprises seek to govern dat

In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.

Visit our pressroom
World GlobeA line styled icon from Orion Icon Library.HiddenA line styled icon from Orion Icon Library.Eye